

P.E.I. Pharmacare Bulletin

Issue (2018-3)

May 14, 2018

NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY (Effective Date: May 28, 2018)

Product (Generic Name)	Product (Brand Name)	Strength	Dosage Form	DIN	MFR		
Escitalopram	<u>Cipralax and various generics</u>	10 mg 20 mg	Tablet Tablet	Various	Various		
						Criteria	Open benefit
						Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Program, Generic Drug Program, Seniors Drug Program, Nursing Home Program, Catastrophic Drug Program
Fluoxetine	<u>Apo-Fluoxetine</u>	4 mg/1 ml	Oral Solution	02231328	APX		
						Criteria	For the treatment of major depressive disorder. Please see criteria for major depressive disorder in the PEI Pharmacare Formulary under Major Depressive Disorder.
						Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Program, Generic Drug Program, Seniors Drug Program, Nursing Home Program, Catastrophic Drug Program
Ixekizumab	<u>Taltz</u>	80 mg/ml 80 mg/ml	Autoinjector Syringe	02455102 02455110	LIL		
						Criteria	For the treatment of plaque psoriasis. Please see criteria for plaque psoriasis in the PEI Pharmacare Formulary under Plaque Psoriasis Biologic Agents https://www.princeedwardisland.ca/sites/default/files/publications/pei_pharmacare_formulary.pdf
						Program Eligibility	High Cost Drug Program, Catastrophic Drug Program
Levonorgestrel Intrauterine System	<u>Kyleena</u>	19.5 mg	Intrauterine System	02459523	BAY		
						Criteria	Open benefit
						Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Program, Catastrophic Drug Program
Velaglucerase alfa	<u>VPRIV</u>	400 unit	Vial	02357119	SHR		
						Criteria	For patients with Gaucher disease type 1 (GD1)
						Program Eligibility	High Cost Drug Program, Catastrophic Drug Program

IMPORTANT NOTICES

Effective immediately, Minocycline 50 mg and 100 mg capsules (Minocin and various generics) have become open benefits and no longer require Special Authorization.

Effective immediately, Carvedilol 3.125 mg, 6.25 mg, 12.5 mg and 25 mg tablets have become open benefits and no longer require Special Authorization.

Effective immediately, Pramipexole 0.25 mg, 1 mg, and 1.5 mg tablets have become open benefits and no longer require Special Authorization. Pramipexole 0.5 mg tablets will no longer be an eligible benefit under any Pharmacare program.

